- This event has passed.
BioForum – The impact of COVID-19 on the investment environment: How are biotech and pharma adapting?
May 29, 2020 @ 8:30 am - 9:30 am AEST
Event Navigation
The biotechnology, medical technology and pharmaceutical sectors have been unprecedentedly impacted by the current COVID-19 pandemic. In anticipation of a post-COVID world, corporate strategy and business development must be amended accordingly. This BioForum will allow an opportunity to reflect on the impact of COVID-19 on the sector and greater economy, whilst providing insights into how companies can adapt to this ‘new normal’.
Our speaker, Dr Niels Emmerich, Vice President, Global Head of Search and Evaluation at AbbVie Inc. will provide insights into the impact of this pandemic on the current investment environment, and how the sector is adapting to these changes. Niels leverages a deep understanding of the global pharma deal landscape, having held the position of Head of Oncology Search & Evaluation at AbbVie Inc. from 2014-18, and now leads a global team. Abbvie’s Corporate Strategy Office, the Search & Evaluation group, and Niels have enabled a number of strategic transactions that transformed AbbVie Inc.’s pipeline, and have driven licensing, venture and research collaborations with numerous biotech companies.
In addition, Rolf Drohn, Director of EY‘s Tax Policy Centre, will present a general economic/tax update covering the Government Stimulus package, followed by a general discussion with our speakers and additional participants in the Q&A (see below).
This focused event is targeted at those directly involved in business investment, finance and strategy, such as Chief Financial Officers, Chief Executive Officers, Managing Directors, Business Owners, Finance Managers and others in this space.
Event Details
Date: Friday 29 May 2020
Time: 8:30 – 9:40 am
Format: Virtual event – you will receive a link to join via email prior to the event.
Tickets: Members $35, Non Members $45 REGISTRATION IS NOW CLOSED – PLEASE CONTACT OUR OFFICE
We appreciate your ongoing support for the delivery of BioMelbourne Network events.
Speakers:
Dr Niels Emmerich, Vice President, Global Head Search and Evaluation, AbbVie Inc.
Rolf Drohn, Director Tax Policy Centre, EY
Additional Participants in Q&A:
Chris Stemple, Vice President and General Manager of Australia and New Zealand, AbbVie Inc.
Dr Laura Issa, Business Development Search and Evaluation Lead, Australia and New Zealand, AbbVie Inc.
Facilitator:
Denise Brotherton, Partner – Taxation, EY
Read more about our speakers and panelists below.
Cancellation Policy:
Full refund given up to 3 days prior to the event.
No refunds within 3 days of the event.
This event is facilitated by EY.
Dr Niels Emmerich, Vice President, Global Head Search and Evaluation, AbbVie Inc.
Dr Niels Emmerich is Vice President and Global Head of Search & Evaluation at AbbVie Inc, a global, research and development-based biopharmaceutical company committed to developing innovative, advanced therapies for some of the world's most complex and critical conditions. AbbVie’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.
In his capacity as Global Head of Search & Evaluation within the Corporate Strategy Office (CSO), Niels is responsible for forging all investments in external innovation made by AbbVie and provides strategic insights in to emerging areas of research to support these investment decision. Niels leverages a deep understanding of the global pharma deal landscape, having held the position of Head of Oncology Search & Evaluation from 2014-18, and now leader of a global team.
Abbvie’s Corporate Strategy Office, the Search & Evaluation group, and Niels have enabled a number of strategic transactions that transformed AbbVie Inc.’s pipeline, and have driven licensing, venture and research collaborations with numerous biotech companies.
Prior to joining the AbbVie’s corporate strategy function, Niels held several commercial positions at AbbVie, including as Global Commercial Leader - Oncology. Prior to joining AbbVie, Niels was CEO of BioPheresis GmbH, co-founder and COO of Immatics, and worked with McKinsey & Company. Niels will present insights into the impact of COVID on the investment environment and how pharma and biotechs are adapting.
In his capacity as Global Head of Search & Evaluation within the Corporate Strategy Office (CSO), Niels is responsible for forging all investments in external innovation made by AbbVie and provides strategic insights in to emerging areas of research to support these investment decision. Niels leverages a deep understanding of the global pharma deal landscape, having held the position of Head of Oncology Search & Evaluation from 2014-18, and now leader of a global team.
Abbvie’s Corporate Strategy Office, the Search & Evaluation group, and Niels have enabled a number of strategic transactions that transformed AbbVie Inc.’s pipeline, and have driven licensing, venture and research collaborations with numerous biotech companies.
Prior to joining the AbbVie’s corporate strategy function, Niels held several commercial positions at AbbVie, including as Global Commercial Leader - Oncology. Prior to joining AbbVie, Niels was CEO of BioPheresis GmbH, co-founder and COO of Immatics, and worked with McKinsey & Company. Niels will present insights into the impact of COVID on the investment environment and how pharma and biotechs are adapting.
Rolf Drohn, Director Tax Policy Centre, EY
Rolf Drohn has been practicing tax law in Australia for 23 years and specialises in International Tax as well as Tax Policy. Through EY’s Tax Policy Services team he participates in consultations with the Australian Treasury and the Australia Tax Office (ATO). Keen interest in competitive tax policy settings for R&D, Innovation and Productivity including around R&D incentives and treatment of IP. Monitors and analyses new developments, Australia’s response to the OECD’s Base Erosion and Profit Shifting (BEPS) Action Plan covering both international and transfer pricing issues including developments around the pillars of the so called BEPS 2.0 initiative. Leads EY’s German-speaking Business Network in Australia and as a member of EY’s European inbound tax team in Australia he has extensive experience in advising cross-border investors. Vice Chair of the Board of the German Australian Chamber of Industry and Commerce since February 2020
Chris Stemple, Vice President and General Manager of Australia and New Zealand, AbbVie Inc.
Chris Stemple is the Vice President and General Manager of Australia and New Zealand for biopharmaceutical company AbbVie, where he leads a team of more than 300 employees. He is also a member of the AbbVie regional leadership team in Asia.
As a global biopharmaceutical company, AbbVie combines the expertise of a large, established pharmaceutical company with the focus and innovative spirit of a biotech. Through a targeted, patient-centric approach to research and development, AbbVie accelerates new scientific discoveries to address some of the most complex diseases in the world across the areas of immunology, virology, oncology and neuroscience.
Chris is an accomplished senior leader in the biopharmaceutical industry who began his career with a Masters of Science (Genetics) from Melbourne University where he graduated with first class honours, shortly followed by a Masters of Business Administration from Dartmouth College.
Having held several senior roles throughout his 16 years' experience in the pharmaceutical industry, Chris has diverse experience across strategic planning, finance, business development, marketing, sales, market access and regulatory affairs. He has a reputation for building extraordinary teams and providing them with rewarding opportunities for development.
Chris is a Graduate of the Australian Institute of Company Directors and a Board member of the Australian pharmaceutical industry association Medicines Australia.
As a global biopharmaceutical company, AbbVie combines the expertise of a large, established pharmaceutical company with the focus and innovative spirit of a biotech. Through a targeted, patient-centric approach to research and development, AbbVie accelerates new scientific discoveries to address some of the most complex diseases in the world across the areas of immunology, virology, oncology and neuroscience.
Chris is an accomplished senior leader in the biopharmaceutical industry who began his career with a Masters of Science (Genetics) from Melbourne University where he graduated with first class honours, shortly followed by a Masters of Business Administration from Dartmouth College.
Having held several senior roles throughout his 16 years' experience in the pharmaceutical industry, Chris has diverse experience across strategic planning, finance, business development, marketing, sales, market access and regulatory affairs. He has a reputation for building extraordinary teams and providing them with rewarding opportunities for development.
Chris is a Graduate of the Australian Institute of Company Directors and a Board member of the Australian pharmaceutical industry association Medicines Australia.
Dr Laura Issa, Business Development Search and Evaluation Lead, Australia and New Zealand, AbbVie Inc.
Dr Laura Issa is responsible for implementing the business development and external innovation partnerships strategy across Australia and New Zealand for AbbVie Inc., a global specialty biopharmaceutical company. In this capacity, Laura engages with stakeholders, entrepreneurs, scientists and investors across the biopharma and medtech innovation ecosystem to establish early stage collaborative research partnerships, licensing opportunities and venture investments that align with AbbVie’s areas of interest, covering immunology, oncology, neuroscience, women’s health and virology.
Laura is passionate about enabling life science research, healthcare innovation, access equality and quality use of medicines. Laura partners with stakeholders to enable the innovation process, in ways that prime the pipeline and ensure we create lasting impact for the Australian economy and for patients. One way we do this is active participation in the Bridge Program and other skills-building initiatives.
Laura bridges science and business, having worked across the academic, biotechnology and pharmaceutical sectors, at all stages of the product life cycle to build value-based partnerships that advance medical research and innovation.
Prior to joining AbbVie, Laura held Senior Business Development and Licensing roles at Aspen Pharmacare and Merck Sharp Dohme, where she led projects across all therapeutics areas and executed partnership deals with local, regional and global companies.
Prior to transitioning to the pharmaceutical industry, Laura was a senior technology transfer and licensing professional with NewSouth Innovations. As a post-doctoral research scientist from 1999-2004, Laura worked with the Children’s Medical Research Institute and held a post-doctoral research fellowship (UNSW) with the Victor Chang Cardiac Research Institute.
Laura achieved a PhD from the Garvan Institute of Medical Research (UNSW, 1999) and Master of Business Administration-Technology (UNSW; 2005). Laura is a Graduate of the Australian Institute of Company Directors.
Laura is passionate about enabling life science research, healthcare innovation, access equality and quality use of medicines. Laura partners with stakeholders to enable the innovation process, in ways that prime the pipeline and ensure we create lasting impact for the Australian economy and for patients. One way we do this is active participation in the Bridge Program and other skills-building initiatives.
Laura bridges science and business, having worked across the academic, biotechnology and pharmaceutical sectors, at all stages of the product life cycle to build value-based partnerships that advance medical research and innovation.
Prior to joining AbbVie, Laura held Senior Business Development and Licensing roles at Aspen Pharmacare and Merck Sharp Dohme, where she led projects across all therapeutics areas and executed partnership deals with local, regional and global companies.
Prior to transitioning to the pharmaceutical industry, Laura was a senior technology transfer and licensing professional with NewSouth Innovations. As a post-doctoral research scientist from 1999-2004, Laura worked with the Children’s Medical Research Institute and held a post-doctoral research fellowship (UNSW) with the Victor Chang Cardiac Research Institute.
Laura achieved a PhD from the Garvan Institute of Medical Research (UNSW, 1999) and Master of Business Administration-Technology (UNSW; 2005). Laura is a Graduate of the Australian Institute of Company Directors.
Denise Brotherton, Partner – Taxation, EY
Denise Brotherton, Partner – Taxation, EY
https://www.linkedin.com/in/denise-brotherton-190559b/
https://www.linkedin.com/in/denise-brotherton-190559b/
